Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated the efficacy and safet...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Maria Paz Garcia-Portilla (Autor), Pierre-Michel Llorca (Autor), Giuseppe Maina (Autor), Vasilis P. Bozikas (Autor), Halise Devrimci-Ozguven (Autor), Sung-Wan Kim (Autor), Paul Bergmans (Autor), Irina Usankova (Autor), Katalin Pungor (Autor)
Format: Llibre
Publicat: SAGE Publishing, 2020-05-01T00:00:00Z.
Matèries:
Accés en línia:Connect to this object online.
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet

Connect to this object online.

3rd Floor Main Library

Detall dels fons de 3rd Floor Main Library
Signatura: A1234.567
Còpia 1 Disponible